This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2000 Oct 4;92(19):1552-3.

doi: 10.1093/jnci/92.19.1552.

Response rates, survival, and chemotherapy trials

R Pazdur

PMID: 11018082
DOI: 10.1093/jnci/92.19.1552

Editorial

Response rates, survival, and chemotherapy trials

R Pazdur. J Natl Cancer Inst. 2000.

. 2000 Oct 4;92(19):1552-3.

doi: 10.1093/jnci/92.19.1552.

Author

R Pazdur

PMID: 11018082
DOI: 10.1093/jnci/92.19.1552

No abstract available

PubMed Disclaimer

Comment on

A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.
Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. Chen TT, et al. J Natl Cancer Inst. 2000 Oct 4;92(19):1601-7. doi: 10.1093/jnci/92.19.1601. J Natl Cancer Inst. 2000. PMID: 11018096

Similar articles

Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.
Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P; Mata-analysis Group in Cancer. Buyse M, et al. J Natl Cancer Inst. 2001 Mar 7;93(5):399-401. doi: 10.1093/jnci/93.5.399. J Natl Cancer Inst. 2001. PMID: 11238707 No abstract available.
Model aims to reduce discrepancy between phase II, phase III trials.
Reynolds T. Reynolds T. J Natl Cancer Inst. 2000 Oct 4;92(19):1554-5, 1556. doi: 10.1093/jnci/92.19.1554. J Natl Cancer Inst. 2000. PMID: 11018083 No abstract available.
The role of cisplatin in the treatment of small-cell lung cancer?
Berghmans T, Paesmans M, Sculier JP. Berghmans T, et al. Ann Oncol. 2001 May;12(5):585-6. doi: 10.1023/a:1011157008014. Ann Oncol. 2001. PMID: 11432613 No abstract available.
[Lung cancer].
Ono A, Yamamoto N. Ono A, et al. Gan To Kagaku Ryoho. 2007 Mar;34(3):367-73. Gan To Kagaku Ryoho. 2007. PMID: 17353626 Review. Japanese.
Second line treatment (2 LT) in small cell lung cancer (SC).
Clerici M. Clerici M. Anticancer Res. 1994 Jan-Feb;14(1B):337-9. Anticancer Res. 1994. PMID: 8166479 Review.

See all similar articles

Cited by

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials.
Aprile G, Fontanella C, Bonotto M, Rihawi K, Lutrino SE, Ferrari L, Casagrande M, Ongaro E, Berretta M, Avallone A, Rosati G, Giuliani F, Fasola G. Aprile G, et al. Oncotarget. 2015 Oct 6;6(30):28716-30. doi: 10.18632/oncotarget.4747. Oncotarget. 2015. PMID: 26308250 Free PMC article. Review.
Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors.
Bagchee-Clark AJ, Mucaki EJ, Whitehead T, Rogan PK. Bagchee-Clark AJ, et al. MedComm (2020). 2020 Dec 10;1(3):311-327. doi: 10.1002/mco2.46. eCollection 2020 Dec. MedComm (2020). 2020. PMID: 34766125 Free PMC article.
Inferences of individual drug responses across diverse cancer types using a novel competing endogenous RNA network.
Zhang Y, Li X, Zhou D, Zhi H, Wang P, Gao Y, Guo M, Yue M, Wang Y, Shen W, Ning S, Li Y, Li X. Zhang Y, et al. Mol Oncol. 2018 Sep;12(9):1429-1446. doi: 10.1002/1878-0261.12181. Epub 2018 Jul 14. Mol Oncol. 2018. PMID: 29464864 Free PMC article.
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Foster NR, et al. Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960500 Free PMC article.
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, Wheler J, Kurzrock R. Jain RK, et al. J Clin Oncol. 2012 Jul 20;30(21):2684-90. doi: 10.1200/JCO.2011.36.4752. Epub 2012 Jun 11. J Clin Oncol. 2012. PMID: 22689801 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems